BridgeBio Oncology Therapeutics Inc. (BBOT) Earnings History
Annual and quarterly earnings data from 2021 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export BBOT earnings history in CSV or JSON format
Free sign-in required to download data
BridgeBio Oncology Therapeutics Inc. (BBOT) Earnings Overview
As of March 1, 2026, BridgeBio Oncology Therapeutics Inc. (BBOT) reported trailing twelve-month net income of -$115M. The company earned $-4.89 per diluted share over the past four quarters.
Looking at the long-term picture, BBOT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3,520 in fiscal 2022.
BridgeBio Oncology Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including RVMD (-$1.13B net income), INCY ($1.29B net income, 0.3% margin), GMAB ($6.57B net income, 0.4% margin), BBOT has comparable earnings metrics. Compare BBOT vs RVMD →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$74M | -14.8% | -$81M | $0.46 | - | - |
| 2023 | -$65M | -1837939.8% | -$65M | $-0.00 | - | - |
| 2022 | $-3,520 | +91.9% | $-3,520 | $0.00 | - | - |
| 2021 | $-43,357 | - | $-43,357 | $-0.00 | - | - |
See BBOT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BBOT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BBOT vs AGIO
See how BBOT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BBOT growing earnings?
BBOT TTM EPS: $-4.89. Net income: $-115M. Earnings growth: N/A.
What are BBOT's profit margins?
BridgeBio Oncology Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are BBOT's earnings?
BBOT earnings data spans 2021-2024. The current earnings trend is N/A YoY. Historical data enables comparison across business cycles.